Receive instant alerts for news on your actions. Claim your 1-week free trial for StreetInsider Premium here.
Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic drug company focused on the development of transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced three key executive appointments . These experienced executives will support the company’s growth and further strengthen the company’s strong clinical development capabilities in managing its strong pipeline.
Maria tornsen joins Passage Bio as Commercial Director, effective today. She reports to the President and CEO of Passage Bio, Bruce Goldsmith, Ph.D., and is a member of the management team. She is responsible for leading and developing the organization and business strategy of the company, including determining product positioning and marketing channels. Prior to joining Passage Bio, Ms. Törnsén, who has nearly 20 years of global business experience, was at Sarepta Therapeutics, where she was Senior Vice President, General Manager, United States.
Simona King will join Passage Bio as Chief Financial Officer (CFO), effective August 23. She will report to Dr Goldsmith and will be a member of the management team. She will be responsible for finance, accounting, tax, treasury, investor relations and information technology functions. Ms. King, former Executive Vice President and Chief Financial Officer of Tmunity Therapeutics, has over 20 years of experience in strategic pharmaceutical and biotechnology finance.
Mark Forman, MD, Ph.D., will join Passage Bio as medical director as of July 30. He will report to Director of Research and Development Eliseo Salinas, MD, MSc., And will be responsible for leading the company’s translational and clinical development efforts. Dr. Forman has nearly two decades of experience in translational research for neurological disorders, having served as head of translational medicine at Acadia and translational research for neuroscience at Merck. He will join Passage Bio from the Alzheimer’s Drug Discovery Foundation (ADDF), where he oversaw the drug discovery and development portfolio.
“I am delighted that we are able to bring these highly experienced professionals into our business, further enhancing our already talented management team,” said Dr. Goldsmith. “Passage Bio’s robust and expanding pipeline presents a significant opportunity in both clinical development and business planning to ensure optimal patient adoption once our therapies are approved. I am delighted that we have such strong leadership to expertly drive the growth of our business and advance our patient portfolio. “
Mrs Törnsén has nearly 20 years of global business experience in the pharmaceutical and biotechnology industry, working in both rare and specialized therapeutic areas and in multiple geographic markets. As US CEO of Sarepta, she led the launch of its second and third Duchenne muscular dystrophy products. She also led preparations for the launch of future gene therapies and double-digit year-over-year sales growth in 2019 and 2020, with responsibility for marketed and pipeline products. Prior to Sanofi Genzyme, she worked at Shire in rare disease marketing before joining the neuroscience division. While at Shire, she moved to the United States and led sales and marketing in the United States for the Endocrine franchise. Prior to joining Shire, Ms. Törnsén worked at Merck KGaA in Switzerland, where she held several marketing leadership positions in neurology. She started her career in the industry as a sales representative at Eli Lilly in Sweden, launching three products. She obtained her Masters in International Business Administration from Lund University in Sweden.
Mrs. King has more than 20 years of experience in strategic finance in the pharmaceutical and biotechnology industry, with small and large companies. His experience ranges from advising management teams on growth strategies to managing equity and debt financing to successful product launches. She will join Passage Bio from Tmunity Therapeutics, where she held the position of Chief Financial Officer. Previously, she was at Emergent BioSolutions as Vice President of Financial Planning, Analysis and Assistant Treasurer. Prior to Emergent, she worked for 19 years at Bristol-Myers Squibb, holding a number of increasingly responsible financial positions in most functional aspects of the organization including mergers and acquisitions, R&D, commerce and manufacturing. , eventually leading the company’s global financial processes as executive director of corporate financial planning and analysis. Ms. King is a chartered accountant. She received her BA from Kalamazoo College and her MBA from Columbia Business School. She also graduated in African Studies from the University of Cape Town, where she was a Rotary Ambassador Fellow.
Dr Forman led the ADDF Scientific Affairs team which oversees the drug discovery and development portfolio. Dr Forman is a neuropathologist and neuroscientist who, prior to joining ADDF, was Vice President at Acadia Pharmaceuticals, where he was responsible for translational medicine, responsible for preclinical and early clinical development and contributed to the development of pimavanserin for treatment hallucinations and delusions. associated with dementia-related psychosis. Dr Forman also spent 12 years at Merck, where he was Executive Director and Head of Neuroscience in Translational Medicine, responsible for the portfolio of Neurosciences in Early Clinical Development, including contributions to the development of over 20 new therapies and multiple applications of new drugs. Dr Forman has been a member of the Scientific Advisory Board for Biomarkers and FTD Treatment of the Association for Frontotemporal Dementia since 2012. Dr Forman received his PhD. at Rockefeller University, MD at Duke University and BS at Yale University.